Novo Nordisk A/S had a robust growth in operating profit in the first quarter, even taking into account the cost of integrating the recently acquired Dicerna Pharmaceuticals Inc, a developer of candidate RNA interference (RNAi) therapeutics. Novo completed the purchase of Dicerna on 28 December 2021 and since then has been absorbing the costs. The deal grew out of a collaboration between the two companies where they have been exploring more than 30 liver cell targets for the treatment of disorders such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes, obesity and rare diseases.
